Pfizer BioNtech vaccine
A decision is expected next month by European Health Regulators on the use of the Pfizer BioNtech Covid-19 vaccine on children under 12.
The EMA is examining an application to authorise its use on children, aged 5 to 11.
Marco Cavaleri of the EMA, says a decision should be made in December unless additional data is needed:
#Comirnaty for children aged 5 to 11: conclusion expected in December. This is a shortened timetable compared to similar reviews. We will also consider further data collected and submitted by BioNTech/Pfizer from an ongoing paediatric trial. #EMAPresser
— EU Medicines Agency (@EMA_News) November 4, 2021
Yesterday it was announced children as young as 5 will be offered Covid-19 vaccinations in the United States.
The Centres for Disease Control and Prevention recommended the rollout of the Pfizer-BioNtech vaccine, to children aged 5 - 11.
The recommendation will now expand vaccine access to approximately 28 million children in the US.
Vaccinations can begin immediately.
Children under 12 will receive a paediatric dose, which is one third the dosage of an adult vaccine.
